UCB Pharma (Belgium)

Recent papers from UCB Pharma (Belgium)

1. BigpictureQC: multi-stain, multi-species artifact segmentation for whole-slide quality controlBMC Medicine · 2026
2. A large-scale consensus study of a diagnostic algorithm for canine and feline mammary tumor histopathology: An attempt to improve inter-observer agreementVeterinary Pathology · 2026
3. Comparing Virtual Reality Headsets With Standard Diagnostic Workstations for MRI Grading of Knee Meniscus Lesions: A Small‐Scale Pilot StudyiRadiology · 2026
4. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialThe Lancet · 2021
5. JTpeak, a valuable proarrhythmic risk biomarker in telemetered dogs to differentiate pure hERG from multi-ion channel blockersJournal of Pharmacological and Toxicological Methods · 2026
6. Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop ReportClinical Pharmacology & Therapeutics · 2026
7. In Vitro Comparison of Microenvironmental pH Modulation Approaches for MinzasolminPharmaceutics · 2026
8. Benchmarking model-based design of experiment approaches with a pharmaceutical crystallisation emulatornpj Computational Materials · 2026
9. Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label ExtensionArthritis & Rheumatology · 2026
10. Impact of bimekizumab on CANDEN spinal MRI inflammation and structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 resultsLara D. Veeken · 2026
11. Bimekizumab Demonstrated Comparable 1-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from 2 Phase 3 StudiesThe Journal of Rheumatology · 2026
12. Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2B and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year UpdateThe Journal of Rheumatology · 2026
13. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USADrugs - Real World Outcomes · 2026
14. Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label studyArthritis & Rheumatology · 2026
15. At-home EEG-based sleep monitoring in people living with Lennox-Gastaut syndrome: The HEADFIRST studyEpilepsy & Behavior · 2026
16. WONOEP appraisal: Biomarkers and treatment strategies beyond the synapseEpilepsia · 2026
17. Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic ArthritisThe Journal of Rheumatology · 2026
18. Measurement properties of the FATIGUE-PRO in patients with SLE in real-world settingsLupus Science & Medicine · 2026
19. Nerpa 2: probabilistic linking of biosynthetic gene clusters to nonribosomal peptidesBioinformatics · 2026
20. Expertise of European Clinical Trial Units in Conducting and Managing Cross-Border Pediatric Clinical Trials for Rare DiseasesTherapeutic Innovation & Regulatory Science · 2026